Craig Fraser, CEO of Windtree Therapeutics, Inc. WINT, engaged in a recent interview with Benzinga.
Windtree is pushing forward with late-stage interventions for cardiovascular disorders. The primary goal is to provide effective treatment for patients in critical situations.
Utilizing innovative scientific and clinical methodologies, Windtree is constructing a multi-asset portfolio centered around compounds capable of activating SERCA2a, which holds immense importance for patients encountering acute cardiac episodes. Its flagship candidate, istaroxime, is undergoing development as a pioneering treatment for cardiogenic shock and acute heart failure.
Mr. Fraser expounded upon his company’s recent collaboration with Lee’s Pharmaceuticals, a strategic move aimed at bolstering Windtree’s efforts in therapy development and commercialization.
For additional details, click here:
Photo courtesy of Robina Weermeijer on Unsplash.
This post includes sponsored content. Its purpose is solely informational and does not serve as investment advice.
